Michelle A. Blaskovich

4.0k citations

44 papers · 3.3k indexed · 1 hit paper · h-index 27

Co-authors: Saı̈d M. Sebti Jiazhi Sun Andrew D. Hamilton Richard Jove James Turkson Yimin Qian Alan Cantor Domenico Coppola
Topics: Protein Kinase Regulation and GTPase Signaling (16 papers)Cancer-related Molecular Pathways (9 papers)Peptidase Inhibition and Analysis (7 papers)
Cited by: Toxicology Oncology Molecular Biology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Journal of Clinical Oncology
Partner nations: United States United Kingdom Australia

In The Last Decade

Michelle A. Blaskovich

44 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

2007 616 citations Michelle A. Blaskovich, Harshani R. Lawrence et al. profile →

Peers

Countries citing papers authored by Michelle A. Blaskovich

Since Specialization

Citations

This map shows the geographic impact of Michelle A. Blaskovich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle A. Blaskovich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle A. Blaskovich more than expected).

Fields of papers citing papers by Michelle A. Blaskovich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle A. Blaskovich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle A. Blaskovich. The network helps show where Michelle A. Blaskovich may publish in the future.

Co-authorship network of co-authors of Michelle A. Blaskovich

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle A. Blaskovich. A scholar is included among the top collaborators of Michelle A. Blaskovich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle A. Blaskovich. Michelle A. Blaskovich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients. 2024 ·Journal of Clinical Oncology ·(unknown),Amod A. Sarnaik,John M. Kirkwood,James Larkin,Jeffrey S. Weber,Michelle A. Blaskovich,Kranthi Kunkalla,Rana Fiaz,Giri Sulur,Jeffrey Chou,Hequn Yin	1
2	Lysophosphatidic Acid Acyltransferase Beta Regulates mTOR Signaling 2013 ·PLoS ONE ·Michelle A. Blaskovich,(unknown),Harshani R. Lawrence,Nicholas J. Lawrence,Saı̈d M. Sebti,Gregory M. Springett	19
3	Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) 2012 ·Journal of Translational Medicine ·(unknown),Thomas F. Gajewski,April K.S. Salama,Donna Niedzwiecki,Jeffrey Johnson,Gerald P. Linette,(unknown),Michelle A. Blaskovich,Saı̈d M. Sebti,Frank G. Haluska	56
4	Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase 2009 ·Chemistry & Biology ·Michael A. Hast,Steven Fletcher,(unknown),(unknown),Michelle A. Blaskovich,Kasey Rivas,Michael H. Gelb,Wesley C. Van Voorhis,Saı̈d Sebti,Andrew D. Hamilton,L.S. Beese	29
5	Module Assembly for Protein‐Surface Recognition: Geranylgeranyltransferase I Bivalent Inhibitors for Simultaneous Targeting of Interior and Exterior Protein Surfaces 2008 ·Chemistry - A European Journal ·(unknown),(unknown),Michelle A. Blaskovich,Akiko Yano,Kazuo Harada,Saı̈d M. Sebti,Nobuo Kato,Junko Ohkanda	9
6	Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling 2008 ·Blood ·Pearlie K. Epling‐Burnette,Lubomir Sokol,Xianhong Chen,Fanqi Bai,Junmin Zhou,Michelle A. Blaskovich,JianXiang Zou,Jeffrey S. Painter,(unknown),Lynn C. Moscinski,Jeffrey A. Yoder,Julie Y. Djeu,Saı̈d M. Sebti,Thomas P. Loughran,Sheng Wei	33
7	Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase 2006 ·Organic & Biomolecular Chemistry ·Junko Ohkanda,Corey L. Strickland,Michelle A. Blaskovich,(unknown),Jeffrey W. Lockman,Andreas Vogt,(unknown),Jiazhi Sun,Yimin Qian,David B. Knowles,(unknown),Saı̈d Sebti,Andrew D. Hamilton	9
8	Activation of Dendritic Cells via Inhibition of Jak2/STAT3 Signaling 2005 ·The Journal of Immunology ·Yulia Nefedova,Pingyan Cheng,Daniele M. Gilkes,Michelle A. Blaskovich,Amer A. Beg,Saı̈d M. Sebti,Dmitry I. Gabrilovich	164
9	Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors 2005 ·Oncogene ·Jiazhi Sun,De-an Wang,Rishi K. Jain,Adam Carie,(unknown),(unknown),Michelle A. Blaskovich,Laura Baldini,Domenico Coppola,Andrew D. Hamilton,Saı̈d M. Sebti	87
10	Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity 2005 ·Oncogene ·Jiazhi Sun,Michelle A. Blaskovich,Richard Jove,Sandra Livingston,Domenico Coppola,Saı̈d M. Sebti	228
11	In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability 2004 ·Bioorganic & Medicinal Chemistry ·(unknown),Junko Ohkanda,Howard Kendrick,Kohei Yokoyama,Michelle A. Blaskovich,(unknown),Frederick S. Buckner,Wesley C. Van Voorhis,Debopam Chakrabarti,Simon L. Croft,Michael H. Gelb,Saı̈d Sebti,Andrew D. Hamilton	35
12	Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening 2004 ·Journal of Immunological Methods ·Maura Gasparetto,Tracy Gentry,Saı̈d M. Sebti,Erica O’Bryan,Ramadevi Nimmanapalli,Michelle A. Blaskovich,Kapil N. Bhalla,David A. Rizzieri,Perry Haaland,(unknown),Clay Smith	33
13	Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I 2004 ·Bioorganic & Medicinal Chemistry ·(unknown),Michelle A. Blaskovich,(unknown),Saı̈d M. Sebti,Andrew D. Hamilton	11
14	Inhibitors of Protein Farnesyltransferase as Novel Anticancer Agents 2002 ·Current Topics in Medicinal Chemistry ·Junko Ohkanda,David B. Knowles,Michelle A. Blaskovich,Saı̈d Sebti,Andrew D. Hamilton	66
15	Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity 2001 ·Bioorganic & Medicinal Chemistry Letters ·Junko Ohkanda,Jeffrey W. Lockman,Kohei Yokoyama,Michael H. Gelb,Simon L. Croft,Howard Kendrick,Maria I. Harrell,Jean E. Feagin,Michelle A. Blaskovich,Saı̈d Sebti,Andrew D. Hamilton	61
16	Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice 2000 ·Nature Biotechnology ·Michelle A. Blaskovich,Qing Lin,Frédéric Delarue,Jiazhi Sun,Hyung Soon Park,Domenico Coppola,Andrew D. Hamilton,Saı̈d M. Sebti	119
17	Requirement for Geranylgeranyl Transferase I and Acyl Transferase in the TGF-β-Stimulated Pathway Leading to Elastin mRNA Stabilization 1998 ·Biochemical and Biophysical Research Communications ·Umberto Kucich,Joan C. Rosenbloom,(unknown),William R. Abrams,Michelle A. Blaskovich,Andrew D. Hamilton,Junko Ohkanda,Saı̈d M. Sebti,J. Rosenbloom	21
18	Lovastatin Inhibits the Stimulation of Mitogen-Activated Protein Kinase by Insulin in HIRcB Fibroblasts 1996 ·Archives of Biochemistry and Biophysics ·Xiaoqin Xu,Terence F. McGuire,Michelle A. Blaskovich,Saı̈d M. Sebti,Guillermo Romero	37
19	Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes 1995 ·Journal of Biological Chemistry ·Edwina C. Lerner,Yimin Qian,Michelle A. Blaskovich,Renae D. Fossum,Andreas Vogt,Jiazhi Sun,Adrienne D. Cox,Channing J. Der,Andrew D. Hamilton,Saı̈d M. Sebti	314
20	A Non-peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing 1995 ·Journal of Biological Chemistry ·Andreas Vogt,Yimin Qian,Michelle A. Blaskovich,Renae D. Fossum,Andrew D. Hamilton,Saı̈d Sebti	95

About Michelle A. Blaskovich

Michelle A. Blaskovich is a scholar working on Oncology, Molecular Biology and Genetics, having authored 44 papers that have together received 3.3k indexed citations. Recurring topics across this work include Protein Kinase Regulation and GTPase Signaling (16 papers), Cancer-related Molecular Pathways (9 papers) and Peptidase Inhibition and Analysis (7 papers). The work is most often cited by research in Toxicology (178 citations), Oncology (1.4k citations) and Molecular Biology (1.9k citations). Michelle A. Blaskovich has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Saı̈d M. Sebti, Jiazhi Sun, Andrew D. Hamilton, Richard Jove, James Turkson, Yimin Qian, Alan Cantor, Domenico Coppola, Junko Ohkanda and Andreas Vogt. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact